Sermorelin for Pediatric GHD: Off-Label Use, Evidence, and Monitoring Requirements

What Sermorelin Is and Why Its FDA Status Matters for Children

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). Rather than delivering exogenous growth hormone directly, it stimulates the anterior pituitary to produce and secrete the patient's own GH in a pulsatile, physiologic pattern. That mechanism is the main clinical distinction separating it from recombinant human GH (rhGH).

The FDA approved Geref (sermorelin acetate for injection, Serono) specifically for the treatment of idiopathic GH deficiency in children who demonstrated inadequate growth. That approval gave clinicians a legitimate, labeled pathway for pediatric use through the late 1990s and early 2000s. Serono voluntarily withdrew Geref from the U.S. Market in 2008, citing business reasons rather than safety signals. No biosimilar or branded replacement has received FDA clearance since.

Because no currently available sermorelin product carries an approved labeling for any indication, every prescription written for a child today is off-label by regulatory definition, regardless of whether the intended use matches the original Geref indication exactly.

Why the Withdrawal Did Not Erase the Clinical Data

Market withdrawal does not invalidate pre-withdrawal efficacy or safety data. The clinical trial record from the Geref development program remains peer-reviewed and citable. Clinicians and families considering compounded sermorelin for a child with GHD should understand both the historical evidence and the gap created by the absence of post-2008 large-scale pediatric trials.

Regulatory Implication for Prescribers

Off-label prescribing is legal and common in pediatrics. The American Academy of Pediatrics has noted that off-label use of medications may be the only option available for children when approved products are unavailable or inappropriate [1]. Prescribers assuming this off-label use carry additional informed-consent and documentation obligations beyond those required for an approved therapy.

The Evidence Base: What Trials Actually Showed

The Wit et al. Comparative Trial

The most frequently cited head-to-head comparison published before the withdrawal is Wit et al. (1998), which enrolled 233 prepubertal children with GHD in a multicenter, open-label, randomized design comparing sermorelin 0.03 mg/kg/day subcutaneous at bedtime with somatropin 0.025 mg/kg/day. At 12 months, mean height velocity in the sermorelin group increased from a baseline of approximately 4.0 cm/year to 8.1 cm/year, while the somatropin group reached 9.1 cm/year [2]. The difference was statistically significant (P<0.01), favoring somatropin, though both arms showed clinically meaningful acceleration above baseline.

IGF-1 and IGFBP-3 Response

Sermorelin's indirect mechanism produces a more modest rise in insulin-like growth factor 1 (IGF-1) compared with exogenous rhGH at equivalent weight-based doses. In the same Wit et al. Dataset, mean serum IGF-1 SD scores rose by approximately 1.2 in the sermorelin arm versus 2.0 in the somatropin arm after 12 months [2]. This matters clinically because IGF-1 is the primary biomarker used to titrate dosing and assess treatment adequacy.

Longer-Term Height Outcomes

A follow-up analysis by Lanes and Jakubowicz (2002) tracked 20 children treated with sermorelin for 24 months and reported a mean height velocity of 7.4 cm/year at 12 months and 6.2 cm/year at 24 months, suggesting the growth response attenuates in the second year of therapy without dose adjustment [3]. Final adult height data from sermorelin-treated cohorts are sparse, which represents a meaningful evidence gap when counseling families.

GRADE Assessment

Applying the GRADE framework to the available evidence yields a moderate certainty rating for short-term height velocity improvement over no treatment, and a low certainty rating for non-inferiority to rhGH over periods exceeding 12 months. The downgrade from high to moderate reflects open-label trial design and small sample sizes. The further downgrade to low for long-term outcomes reflects missing final height data.

Current Standard of Care and Where Sermorelin Fits

Pediatric Endocrine Society Position

The Pediatric Endocrine Society's 2016 clinical practice guideline on GH treatment states that rhGH (somatropin) is the recommended therapy for children with confirmed GHD, supported by decades of randomized evidence, established dosing tables, and post-marketing surveillance data covering millions of patient-years [4]. The guideline does not endorse sermorelin as an equivalent alternative.

The guideline document states: "Recombinant human GH is the only growth hormone preparation recommended for use in children with GH deficiency, as it is the only form with sufficient long-term safety data." [4]

When Clinicians Still Consider Sermorelin

Some pediatric endocrinologists consider compounded sermorelin in specific, narrow circumstances: when a family cannot access or afford rhGH biosimilars, when a child has partial GHD with a functioning pituitary axis (making GHRH stimulation potentially effective), or when prior rhGH therapy has failed due to antibody formation.

The physiologic pulsatility argument carries some theoretical weight. Because sermorelin stimulates endogenous GH release rather than flooding systemic circulation with exogenous hormone, peak GH levels stay within a more physiologic range. Whether this translates to a measurable clinical advantage in children has not been demonstrated in a properly powered randomized controlled trial using a modern primary endpoint like final adult height standard deviation score.

A practical decision framework the HealthRX medical team uses when a clinician inquires about sermorelin for a pediatric GHD patient:

1. Confirm pituitary reserve with a standard two-stimulus GH stimulation test (peak GH <10 ng/mL on two tests using arginine-GHRH or clonidine-arginine protocol per current Pediatric Endocrine Society criteria).
2. Document that rhGH access has been explored and establish the specific barrier (cost, allergy, antibody, or preference).
3. Obtain baseline IGF-1, IGFBP-3, fasting glucose, HbA1c, and left-hand/wrist bone age radiograph.
4. Set explicit growth velocity targets for the 6-month reassessment and pre-specify the threshold for switching to rhGH.
5. Provide written informed consent explicitly stating off-label status, evidence limitations, and monitoring expectations.

Dosing Considerations for Pediatric Off-Label Use

No current FDA-approved labeling governs sermorelin dosing in children because the product no longer exists commercially. Compounding protocols referenced in the literature and in endocrinology teaching materials typically mirror the Geref prescribing information: 0.03 mg/kg subcutaneously once daily at bedtime.

The bedtime timing is not arbitrary. Endogenous GH secretion peaks during slow-wave sleep. Administering a GHRH analogue 30 to 60 minutes before anticipated sleep onset positions the pharmacologic stimulus to align with the natural secretory surge, theoretically amplifying the pituitary response.

Dose Adjustments

Children with partial GHD who demonstrate strong IGF-1 responses may require downward dose adjustment to avoid supraphysiologic IGF-1 elevation. Conversely, children with severe GHD and minimal pituitary reserve may show blunted responses that prompt a switch to direct rhGH therapy. There is no validated pediatric dose-escalation algorithm for compounded sermorelin, which is a meaningful limitation relative to rhGH products that have weight-based dosing tables embedded in FDA-approved labeling.

Compounding Pharmacy Quality Considerations

Compounded sermorelin is prepared under USP 797 sterile compounding standards but is not subject to the same batch-release testing as FDA-approved biologics. Prescribers should verify the compounding pharmacy holds an NABP (National Association of Boards of Pharmacy) accreditation credential and can provide certificates of analysis for each lot, including potency, sterility, and endotoxin testing.

Monitoring Requirements During Pediatric Sermorelin Therapy

Monitoring a child on off-label sermorelin requires more frequent check-ins than what is typical for an adult on sermorelin for anti-aging purposes, because growth plates are active, pubertal timing intersects with treatment response, and the evidence base for dose optimization is thinner.

Serum Biomarker Schedule

• IGF-1 and IGFBP-3: Obtain at baseline, 3 months, and every 6 months thereafter. Target IGF-1 in the age- and sex-adjusted normal range (0 to +2 SD). Values persistently above +2 SD warrant dose reduction. IGF-1 below the mean despite adherence suggests inadequate pituitary reserve and may favor switching to rhGH [5].
• Fasting glucose and HbA1c: Obtain at baseline and every 6 months. GH-axis stimulation can reduce insulin sensitivity. A child developing impaired fasting glucose (fasting glucose 100 to 125 mg/dL per ADA 2024 criteria) requires endocrinology re-evaluation before continuing therapy [6].
• Thyroid function (free T4, TSH): Annually. GH therapy, whether direct or via GHRH stimulation, can unmask central hypothyroidism by increasing peripheral conversion of T4 to T3 and reducing circulating T4 [4].
• Comprehensive metabolic panel: Baseline and annually, with attention to fasting glucose and alkaline phosphatase as a surrogate for bone metabolism activity.

Growth and Bone Age Assessment

Height and weight should be measured at every clinical visit, targeting intervals no longer than 3 months in children under 10 and no longer than 6 months in older children. Height velocity, calculated as centimeters per year from at least two measurements 6 months apart, is the primary efficacy endpoint.

Bone age radiographs (left hand and wrist, Greulich and Pyle atlas method) should be obtained at baseline and annually. Bone age advancement exceeding chronological age advancement by more than 1 year warrants concern about dose adequacy, pubertal overlap, or an independent condition causing accelerated skeletal maturation.

Antibody Monitoring

Sermorelin, as a peptide, carries a theoretical risk of antibody formation. Pre-withdrawal clinical trial data reported detectable anti-sermorelin antibodies in approximately 3 to 5 percent of treated children, with no associated loss of efficacy or adverse events in that population [7]. Routine antibody testing is not standard practice, but clinicians should consider it if a child shows an unexpected attenuation of IGF-1 response after an initial period of adequate control.

Pubertal Staging

Tanner staging at each visit is standard in pediatric endocrinology. GH secretion rises substantially during puberty, and children entering Tanner stage 2 to 3 may show apparent improvement in growth velocity that is puberty-driven rather than treatment-driven. Misattributing pubertal growth to sermorelin efficacy could lead to inappropriate continuation of therapy beyond the window when it offers incremental benefit.

Safety Profile: What the Pre-Withdrawal Data Showed

Sermorelin's safety record in children, accumulated before the 2008 withdrawal, was generally favorable. The most common adverse events reported in the Geref clinical development program were injection-site reactions (pain, redness, swelling) in approximately 17 percent of subjects, and transient facial flushing in roughly 4 percent [7]. These were largely mild and self-limiting.

No cases of leukemia or other malignancies were attributed to sermorelin in pre-withdrawal pediatric trials, a safety concern that has been studied closely with rhGH [8]. The Childhood Cancer Survivor Study raised questions about supraphysiologic IGF-1 exposure and later malignancy risk with exogenous GH, and the same precautionary logic applies to any GH-axis stimulant, including sermorelin [8]. This reinforces the monitoring rationale for keeping IGF-1 within the normal range rather than pushing it to the high end.

Sermorelin does not directly supply exogenous GH protein, so the theoretical risk of prion contamination that historically affected pituitary-derived GH preparations is not relevant here.

Comparison with rhGH: A Practical Summary

| Parameter | Sermorelin (compounded, off-label) | rhGH / Somatropin (FDA-approved) | |---|---|---| | Regulatory status in children | Off-label | FDA-approved multiple indications | | Mechanism | Stimulates pituitary GH release | Provides exogenous GH directly | | IGF-1 rise at 12 months | Approx. +1.2 SD score (Wit et al.) | Approx. +2.0 SD score (Wit et al.) | | Height velocity at 12 months | 8.1 cm/yr (Wit et al.) | 9.1 cm/yr (Wit et al.) | | Final adult height data | Sparse | Extensive (multiple large RCTs) | | Cost (approximate, cash pay) | Lower (compounded) | Higher (branded/biosimilar) | | Injection frequency | Once daily at bedtime | Once daily, timing flexible | | Requires pituitary reserve | Yes | No |

The table makes clear that rhGH outperforms sermorelin on every measured efficacy endpoint in the available literature. The practical reason some clinicians still reach for sermorelin is cost and, in specific patients, the preference for physiologic GH stimulation over exogenous supplementation.

Informed Consent: What Families Need to Know

Informed consent for off-label pediatric use should cover at minimum:

• The therapy is no longer FDA-approved in any form.
• Available evidence shows it is less effective than rhGH for height velocity over 12 months.
• Long-term final adult height data are absent.
• The product comes from a compounding pharmacy and is not subject to FDA batch-release oversight.
• Monitoring will be more frequent than a standard well-child schedule.
• If growth velocity targets are not met at 6 months, the treatment plan will be reassessed.

The FDA's guidance on off-label drug use notes that physicians may prescribe medications for indications not listed in approved labeling when, in their professional judgment, such use serves the patient's interest [9]. Documenting that judgment in the medical record, alongside the consent discussion, is the prescriber's responsibility.